Invivyd, Inc.
General ticker "IVVD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $109.5M (TTM average)
Invivyd, Inc. follows the US Stock Market performance with the rate: 37.1%.
Estimated limits based on current volatility of 4.0%: low 2.10$, high 2.27$
Factors to consider:
- Total employees count: 95 (+10.5%) as of 2023
- Top business risk factors: Lack of profitability, Cybersecurity threats, Disruption to business operations, Regulatory and compliance, Strategic risks and growth management
- Current price 96.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.32$, 1.13$]
- 2025-12-31 to 2026-12-31 estimated range: [0.34$, 1.14$]
Financial Metrics affecting the IVVD estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.25 > -0.66
- Positive: 41.86 < Shareholder equity ratio, % of 52.15 <= 63.39
- Negative: Operating cash flow per share per price, % of -304.94 <= 0.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term IVVD quotes
Long-term IVVD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $25.38MM |
| Operating Expenses | $212.76MM | $202.26MM |
| Operating Income | $-212.76MM | $-176.88MM |
| Non-Operating Income | $14.12MM | $6.95MM |
| R&D Expense | $163.63MM | $137.25MM |
| Income(Loss) | $-198.64MM | $-169.93MM |
| Profit(Loss)* | $-198.64MM | $-169.93MM |
| Stockholders Equity | $177.47MM | $67.54MM |
| Assets | $229.18MM | $129.51MM |
| Operating Cash Flow | $-173.16MM | $-170.49MM |
| Capital expenditure | $0.61MM | $0.14MM |
| Investing Cash Flow | $280.68MM | $-0.14MM |
| Financing Cash Flow | $1.04MM | $39.33MM |
| Earnings Per Share** | $-1.81 | $-1.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.